Christina S. Baik - Concepedia

Author

Christina S. Baik

Also Known As

Baik, Christina S., Benjamin Besse, C Baik, C. Baik, C. S. Baik, C.S. Baik, Christina Baik, Christina Baik, MD, MPH, Christina S Baik, Christina S. Baik

198

Publications

Citations

H-Index

Concepts

All Affiliations

University of Washington Fred Hutch Cancer Center Seattle Cancer Care Alliance Seoul National University Hospital Institut Gustave Roussy

About

Christina S. Baik is an author at University of Washington specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	38	2.4K
2	Health Sciences	9	9	541
3	Cell Biology	4	4	124
4	Engineering	2	2	31
5	Public Health	1	1	63

Christina S. Baik

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, New England Journal of Medicine	2018	2.6K
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial David Planchard, Benjamin Besse, Harry J.M. Groen, The Lancet Oncology Multicentre Phase 2MedicineMetronomic TherapyPathologyCancer Treatment	2016	867
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, The Lancet Oncology	2021	428
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, The Lancet Diabetes & Endocrinology MedicineThyroid DiseasePathologyCancer TreatmentThyroid Hormone	2021	330
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis David Planchard, Benjamin Besse, Harry J.M. Groen, Journal of Thoracic Oncology	2021	253
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Clinical Cancer Research	2018	224
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC Julia Kargl, Xiaodong Zhu, Huajia Zhang, JCI Insight	2019	183
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer Cristina P. Rodriguez, Qian Wu, Jenna Voutsinas, Clinical Cancer Research	2019	169
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial Frank Griesinger, Giuseppe Curigliano, Michael Thomas, Annals of Oncology	2022	167
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Journal of Thoracic Oncology	2019	141

Page 1